Quarry LP’s Protagonist Therapeutics PTGX Stock Holding History

Quarry LP’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-750	Closed	-$17.2K	–	1859
2023 Q4	$17.2K	Buy	+750	New	+$13.1K	﹤0.01%	831

Other funds holding PTGX

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Quarry LP's PTGX Position: Q1 2024 in Review

Quarry LP sold out of Protagonist Therapeutics (PTGX) in Q1 2024, closing a stake of 750 shares — an estimated $17.2K sold.

Quarry LP first reported a position in PTGX in Q4 2023 and held it in 1 quarter. The position peaked at $17.2K in Q4 2023. 185 funds tracked by Wall St. Rank hold PTGX as of Q1 2024.

Quarry LP reported no remaining Protagonist Therapeutics position as of Q1 2024 after selling out during the quarter.
Quarry LP sold 750 Protagonist Therapeutics shares in Q1 2024, an estimated $17.2K.
Quarry LP first reported a position in Protagonist Therapeutics in Q4 2023 and held it in 1 quarter.
Quarry LP's Protagonist Therapeutics position peaked at $17.2K in Q4 2023.
185 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2024.

Based on Quarry LP's 13F filing for Q1 2024, filed 15 May 2024.